Morgan, R.J., Jr., Synold, T.W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K., Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasilev, S., McGonigle, K., Longmate, J., Yen, Yen, Y., Chow, W., Somlo, G., Carroll, M., Doroshow, J.H. Phase I trial of tamoxifen, carboplatin, and topotecan in the treatment of recurrent or refractory brain or spinal cord tumors. Neurooncology, in press, 2005.
Rosales, J. and Leong, L.A. Chemotherapy for metastatic colorectal cancer. J. Natl. Comprehensive Cancer Network 3: 525-529, 2005.
Faynsod, M., Wagman, L.D., Longmate, J., Carroll, M., and Leong, L.A. Improved hepatic toxicity profile of portal vein adjuvant hepatic infusional chemotherapy. J. Clin. Oncol. 23: 4876-4880, 2005.
Lim, D.W., Morgan, R.J., Jr., Akman, S., Margolin, K., Carr, B.I., Leong, L., Odujinrin, O., and Doroshow, J.H. Phase I trial of menadiol diphosphate (Vitamin K3) in advanced malignancy. Investigational New Drugs 23: 235-239, 2005.
Morgan, Jr., R.J., Synold, T.W., Gandara, D., Muggia, F., Scudder, S., Reed, E., Margolin, K., Raschko, J., Leong, L., Shibata, S., Tetef, M., Vasislev, S., McGonigle, K., Longmate, J., Yen, Y., Chow, W., Somlo, G., Carroll, M. and Doroshow, J.H. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother. Pharmacol. 54: 283-289, 2004.
Shibata, S.I., Lin, S., Doroshow, J.H., Pezner, R., Chow, W.A., Leong, L.A., Margolin, K.A., McNamara, M.V., Morgan, R.J., Jr., Raschko, J.W., Somlo, G., Tetef, M.L., Yen, Y., Synold, T.W., Pezner, R., Chu, D., Wagman, L., Vora, N., Carroll, M., Lee, S. and Longmate, J. Pilot study of intraoperative and external beam radiation therapy combined with continuous infusion 5-fluorouracil in locally advanced gastrointestinal malignancies. Eur. J. Surg. Oncol. 30: 650-657, 2004.
Chow, W.A., Synold, T.W.,Tetef, M.L., Longmate, J., Frankel, P., Lawrence, J., Al-Kadhimi, Z., Leong, L., Lom, D., Margolin, K., Morgan, R.J., Jr., Raschko, J., Shibata, S., Somlo, G., Twardowski, P., Yen, Y., and Doroshow, J.H. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours for the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.
Somlo, G., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Shibata, S., Chu, P., Forman, S., Lim, D., Twardowski, P., Weitzel, J., Alvarnas, J., Kogut, N., Schriber, J., Fermin, E., Damon, L., and Doroshow, J.H. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.
Openshaw, H., Beamon, K., Synold, T., Longmate, J., Frankel, P., Lawrence, J., Al-Kadhimi, Z., Leong, L., Lim, D., Morgan, R., Margolin, K., Shibata, S., Twardowski, P. and Somlo, G. Neurophysiological study of peripheral neuropathy after high dose paclitaxel: Lack of neuroprotective effect of amifostine. Clin. Cancer Res. 10: 461-467, 2004.
Aparicio, A., Eads, C.A., Leong, L.A., Laird, P.W., Newman, E.M., Synold, T.W., Baker, S.D., Zhao, M., and Weber, J.S. Phase I trial of continuous infusion 5-aza-2’-deoxycytidine. Cancer Chemother. Pharmacol. 51: 231-239, 2003.
Morgan, R.J., Jr., Doroshow, J.H., Synold, T., Lim, D., Shibata, S., Margolin, K., Schwarz, R., Leong, L., Somlo, G., Twardowski, P., Yen, Y., Chow, W., Lin, P., Paz, B., Chu, D., Frankel, P., and Stalter, S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 5896-5901, 2003.
Morgan, R.J., Jr., Newman, E., Sowers, L., Scanlon, K., Harrison, J., Akman, S., Leong, L., Margolin, K., Niland, J., Raschko, J., Somlo, G., Carroll, M., Chow, W., Tetef, M., Hamasaki, V., Yen, Y., and Doroshow, J.H. Phase I study of cis-diamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother. Pharmacol. 51: 459-464, 2003.
Somlo, G., Simpson, J.F., Frankel, P., Chow, W., Leong, L., Margolin, K., Morgan, R., Jr., Raschko, J., Shibata, S., Forman, S., Kogut, N., McNamara, M., Molina, A., Somlo, E. and Doroshow, J.H. Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Brit. J. Cancer 87(3): 281-288, 2002.
Yen, Y., Doroshow, J.H., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, G., Twardowski, P., Frankel, P., Longmate, J., Synold, T., and Newman, E. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea (HU) in combination with gemcitabine (Gem): A California Cancer Consortium Trial. Cancer Chemother. Pharmacol. 50: 353-359, 2002.
Somlo, G., Doroshow, J.H., Ahn, C., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., O'Donnell, M., Smith, E., Tetef, M., Forman, S., Yen, Y., Molina, A., Sniecinski, I. Tandem cycle of high-dose melphalan and cisplatin with peripheral blood progenitor cell support for patients with breast cancer and other malignancies. Biol. Blood Marrow Transplant. 7: 284-293, 2001.
Somlo, G., Doroshow, J.H., Synold, T., Reardon, D., Chow, W., Leong, L., Morgan, R. Jr., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., ter Veer, A. and Forman, S.J. High-dose paclitaxel (T) in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue (PBPC) in patients with high-risk primary and responding metastatic breast carcinoma: Toxicity profile,, relationship to paclitaxel pharmacokinetics and short-term outcome. Brit. J. Cancer, 84: 1591-1598, 2001.
Tetef, M.L., Synold, T.W., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, S., Yen, Y., Groshen, S., Johnson, K., Lenz, H.J., Gandara, D., and Doroshow, J.H. Phase I trial of ninety-six hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin. Cancer Res. 7: 1569-1576, 2001.
Morgan, R.J., Jr., Doroshow, J.H., Leong, L., Schriber, J., Shibata, S., Forman, S., Hamasaki, V., Margolin, K., Somlo, G., Alvarnas, J., McNamara, M., Longmate, J., Raschko, J., Chow, W., Vasilev, S., McGonigle, K., and Yen, Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Biol. Blood Marrow Transplant. 28(9): 859-863, 2001.
Morgan, R.J., Synold, T.W., Carr, B.I., Doroshow, J.H., Womack, E.P., Shibata, S., Somlo, G., Raschko, J.W., Leong, L., McNamara, M., Chow, W., Teter, M.L., Margolin, K., Akman, S., and Longmate, J. Continuous infusion prochlorperazine: Pharmacokinetics, anti-emetic efficacy, and feasibility of high-dose therapy. Cancer Chemother. Pharmacol. 47: 327-332, 2001.
Morgan, R. J., Jr., Braly, P., Leong, L., Shibata, S., Margolin, K., Somlo, G., McNamara, M., Longmate, J., Schinke, S., Raschko, J., Nagasawa, S., Kogut, N., Najera, L., Johnson, D., and Doroshow, J.H. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously-treated patients with advanced ovarian cancer: Long-term follow-up. Gynecol. Oncol. 77: 433-438, 2000.
Shibata, S., Doroshow, J., Chow, W., Coluzzi, P., Hamasaki, V., Leong, L., Morgan, R., Margolin, K., Raschko, J., Somlo, G., Tetef, M., Yen, Y., Forman, S., Molina, A. A phase I study of inhibitor AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother. Pharmacol. 45(5): 423-427, 2000.
Raschko, J.W., Synold, T.W., Chow, P., Coluzzi, P., Hamasaki, V., Leong, L.A., Margolin, K.A., Morgan, R.J., Shibata, S.I., Somlo, G., Tetef, M.L., Yen, Y., ter Veer, A., and Dorosohw, J.H. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. Cancer Chemother. Pharmacol. 46(5): 403-410, 2000.
Tetef, M., Newman, E., Margolin, K., Akman, S., Leong, L., Morgan, R.. Jr.., Raschko, J., Slatkin, N., Somlo, G., Longmate, J., Carroll, M., and Doroshow, J. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46 (1): 19-26, 2000.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported. Last updated: 07/08.
